Antibody levels against tetanus and diphtheria after polychemotherapy for childhood sarcoma: A report from the Late Effects Surveillance System

Paulides, Marios; Stöhr, Wolfgang; Laws, Hans‐Jürgen; Graf, Norbert; Lakomek, M.; Berthold, Frank; Schimrigk, К.; Niggli, Felix; Jürgens, Heribert; Bielack, Stefan; Kościelniak, Ewa; Klingebiel, Thomas; Langer, Thor﻿s﻿ten

doi:10.1016/j.vaccine.2010.12.084

Cited by 16 publications

(10 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies described that 56.8% of patients with hemato-oncologic illnesses (17), 17% of patients with acute lymphoblastic leukemia (20), 82% of pediatric patients with sarcoma after antineoplastic therapy (21) and 70% in Indian pre-school children (22) had completely protective immunity. Loss of immunity to previous vaccinations, necessity and timing of re-immunization remains controversial.…”

Section: Introductionmentioning

confidence: 99%

Immunity Level to Diphtheria in Beta Thalassemia Patients

Jahromi¹,

Rahmanian²,

Sapidkar³

2017

ME-JFM

View full text Add to dashboard Cite

Introduction: Beta thalassemia major which is very common is a principal health problem in Iran. These patients are more often affected by several infections. The aim of the study was to determine the immunity of patients with beta thalassemia major, to diphtheria. Methods: In this case-control study, anti-diphtheria toxin antibody concentration and serum ferritin levels were compared in 224 patients with thalassemia major and in 224 sex and age matched healthy subjects as control group. The serum concentrations of antibody and ferritin were determined by ELISA and CLIA methods, respectively. Subjects who had diphtheria antibody level >0.1 IU/ml were seen to have complete protection, between 0.1 and 0.01 IU/ml as partial protection and <0.01 IU/ml as no protection. For the analysis we used SPSS version 15 software. A two sided P-value less than 0.05 was considered statistically significant. Results: The mean serum anti diphtheria antibody level was lower in patients with beta thalassemia major than in healthy subjects (1.51 ± 1.60 vs 2.10 ± 1.86, p<0.001). Seventy percent and 20.0% of patients and 87.9% and 12.1% of healthy subjects had complete and partial protective serum anti diphtheria level, respectively (p<0.001). Only 24.1% of anti-diphtheria antibody (IgG) was dependent to serum ferritin level in patients group (P< 0.001). Thus serums anti diphtheria antibody decreased 0.001IU/ml, when serum ferritin increased 1ng/ml. Conclusion: In conclusion, patients with beta thalassemia major had lower anti-diphtheria antibody level than healthy subjects. Thus monitoring immunization status and recommendations for vaccine are essential for increased serum anti-diphtheria antibody concentration.

show abstract

Section: Introductionmentioning

confidence: 99%

Immunity Level to Diphtheria in Beta Thalassemia Patients

Jahromi¹,

Rahmanian²,

Sapidkar³

2017

ME-JFM

View full text Add to dashboard Cite

show abstract

“…A decline in vaccine‐derived immunity is also well observed in patients who had undergone hematopoetic stem cell transplantation (HSCT) . Only scarce data are available about the impact of therapy on humoral immunity in patients with solid tumors (ST) . Children diagnosed with ST such as neuroblastoma, medulloblastoma, rhabdomyosarcoma, or germ cell tumors are currently often treated with long‐term chemotherapy combined with high‐dose radiotherapy.…”

Section: Introductionmentioning

confidence: 99%

“…[3] Only scarce data are available about the impact of therapy on humoral immunity in patients with solid tumors (ST). [4] Children diagnosed with ST such as neuroblastoma, medulloblastoma, rhabdomyosarcoma, or germ cell tumors are currently often treated with long-term chemotherapy combined with high-dose radiotherapy. Conditions that may affect the immunity condition after cessation of therapy include acquired immunity before treatment (vaccination status), therapy intensity, type of cancer, and age of the patient.…”

Section: Introductionmentioning

confidence: 99%

Vaccine-Derived Immunity in Children With Cancer-Analysis of Anti-Tetanus and Anti-Diphtheria Antibodies Changes after Completion of Antineoplastic Therapy

Januszkiewicz‐Lewandowska

Gowin

Bocian

et al. 2015

Pediatr Blood Cancer

View full text Add to dashboard Cite

show abstract

“…The incidence of tetanus infection is about one million per year in the world [ 1 ]. Some subjects with sarcoma [ 2 ], immune deficiency disorders [ 1 ], HTLV1 infected [ 3 ], hemodialysis patients [ 4 5 ] had no protective antibody level against tetanus or don't respond sufficiently to tetanus vaccination. In a study conducted by Kruger et al [ 6 ] suggested that 63% of the unprotected hemodialysis patients against tetanus did not respond to a single tetanus vaccination.…”

Section: Introductionmentioning

confidence: 99%

Immunity to tetanus in major beta thalassemia patients

Jahromi

Rahmanian

2015

Clin Exp Vaccine Res

View full text Add to dashboard Cite

PurposePatients with beta thalassemia major are at increased risk for bacterial infections specially splenectomized patients. The aim of this study was to determine the anti-tetanus antibody concentration among patients with beta thalassemia major.Materials and MethodsThe anti-tetanus antibody concentration was investigated in 224 patients with thalassemia major and 224 healthy subjects matched for age and gender. Tetanus antibody and ferritin serum level were determined by enzyme-linked immunosorbent assay method using commercial kits. Subjects who had antibody level ≥ 0.1 IU/mL was defined as complete protection, 0.01 to < 0.1 IU/mL as partial protection and < 0.01 IU/mL as no protection. For the analysis, we used SPSS version 11.5 software. A two-sided p-value less 0.05 was considered statistically significant.ResultsIn patients with beta thalassemia major, antibody level against tetanus was inversely dependent about 29.3% to serum ferritin level. Thus, when serum ferritin increased 1 ng/mL, serum antibody against tetanus decreased 0.002 IU/mL. Mean anti-tetanus (IgG) antibody titers was lower in thalassemia patients compared to healthy subjects (1.53 ± 1.71 vs. 2.02 ± 2.05, p = 0.007) that was no significantly associated to age and gender in both study groups. All of participants had serum antibody level 0.01 IU/mL or greater. The complete protective level of anti-tetanus antibody was lower in thalassemia subjects in compare to healthy persons (71% vs. 87.9%, p < 0.001).ConclusionPatients with thalassemia had lower anti-tetanus antibody level than healthy subjects. Thus the vaccine recommendation seems essential for patients with beta thalassemia major.

show abstract

Antibody levels against tetanus and diphtheria after polychemotherapy for childhood sarcoma: A report from the Late Effects Surveillance System

Cited by 16 publications

References 38 publications

Immunity Level to Diphtheria in Beta Thalassemia Patients

Immunity Level to Diphtheria in Beta Thalassemia Patients

Vaccine-Derived Immunity in Children With Cancer-Analysis of Anti-Tetanus and Anti-Diphtheria Antibodies Changes after Completion of Antineoplastic Therapy

Immunity to tetanus in major beta thalassemia patients

Contact Info

Product

Resources

About